)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Xencor
Xencor (XNCR) investor relations material
Xencor TD Cowen 46th Annual Health Care Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.TD Cowen 46th Annual Health Care Conference summary2 Mar, 2026
Strategic focus and clinical development
Refined clinical strategy in 2024 to prioritize advancing programs into Phase 1 and 2, aiming for commercial-stage assets.
Achieved three INDs in 2025 and launched the global Phase 2b XENITH-UC study in ulcerative colitis.
Maintains strong financial position with over $600 million in cash, supporting internal pipeline decisions.
Emphasizes maximizing outcomes for patients, clinicians, and shareholders through a focused portfolio.
Partnerships provide meaningful royalties and upfronts, enhancing capital efficiency and technology advancement.
Oncology pipeline highlights
XmAb819, a T-cell engager, showed promising activity in clear cell renal cell carcinoma and is progressing toward pivotal development in 2027.
XmAb541, targeting Claudin-6, is being developed for gynecologic and germ cell tumors, with updates expected by year-end.
Expansion of XmAb819 into additional tumor types, including colorectal and non-small cell lung cancer, is underway.
Both lead oncology programs are leveraging expertise in CD3 engagement to balance efficacy and toxicity.
Clinical updates for both programs are planned for the back half of the year.
Autoimmune and immunology pipeline
XmAb942, an anti-TL1A monoclonal antibody, is in a global Phase 2b study for ulcerative colitis, with healthy volunteer data confirming favorable PK/PD and immunogenicity.
XmAb412, a bispecific antibody targeting TL1A and IL-23p19, will present preclinical data in early 2026 and start first-in-human studies in the back half of 2026.
Plamotamab, a CD20 T-cell engager, is being tested in rheumatoid arthritis after regaining rights in 2024, aiming to differentiate from existing CD20 monoclonal antibodies.
XmAb657, a CD19/CD3 molecule, is positioned as a "CAR T in a bottle" for severe autoimmune diseases, with first-in-human studies planned.
Both B-cell targeted T-cell engager programs are ramping up in the clinic, with updates expected later in the year.
Differentiate XmAb942 and XmAb412 IBD strategies
Plamotamab: T-cell engager vs. CD20 mAb benefit?
XmAb657: How to prove CAR T-like efficacy?
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Next Xencor earnings date
Leerink Global Healthcare Conference 202610 Mar, 2026
Xencor
Next Xencor earnings date
Leerink Global Healthcare Conference 202610 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Xencor Inc. is a clinical-stage biopharmaceutical company focused on developing engineered monoclonal antibodies and cytokine therapies for the treatment of cancer and autoimmune diseases. The company utilizes its proprietary XmAb technology to create antibody-based therapies that enhance immune responses or modulate immune activity. Xencor's pipeline includes candidates designed to target specific proteins involved in disease processes, aiming to provide more effective and durable treatments. The company is involved in both internal research and collaborations with other biopharma companies to advance its therapies through clinical trials. The company is headquartered in Monrovia, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage